Fig. 1. A novel multiplex single-cell genomic and immunophenotypic strategy leverages the sensitivity of MRD detection and MRD clonal architecture to identify leukemic and preleukemic subpopulations.

(A) AML samples from different patients are pooled and stained with TotalSeq-D antibody cocktail and fluorescent antibodies. (B) Cells are sorted based on CD34/CD117 expression for stem and progenitors and captured on Mission Bio scDNA-seq platform. (C) Samples are demultiplexed by SNP after sequencing. (D) Unique surface marker expression pattern correlates with mutation or combinations of mutations. (E) Leukemic clones are distinguished from clonal hematopoiesis clones based on the acquisition of additional mutations. Illustration: Ashley Mastin/Science Advances.